0000000001154014

AUTHOR

Giulia Peserico

showing 3 related works from this author

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

2022

Abstract Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveil…

medicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaCancer stageCancer stage; Hepatocellular carcinoma; Surveillance interval; SurvivalInternal medicinemedicineHumansPropensity ScoreSurveillance intervalSurvival analysisHigh risk patientsHepatologybusiness.industryCancer stageLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAGastroenterologyPatient survivalmedicine.diseaseSurvival AnalysisHepatocellular carcinomaPropensity score matchingSurvival AnalysiLiver cancerbusinessMedian survivalHuman
researchProduct

Monofocal hepatocellular carcinoma: How much does size matter?

2020

Background & Aims: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding staging and treatment of large tumours. We aimed at evaluating the appropriate staging and treatment for large (>5 cm) monofocal (HCC). Methods: From the Italian Liver Cancer database, we selected 924 patients with small early monofocal HCC (2-5 cm; SEM-HCC), 163 patients with larger tumours (>5 cm; LEM-HCC) and 1048 intermediate stage patients (BCLC B). Results: LEM-HCC patients had a worse overall survival (OS) than SEM-HCC (31.0 vs 49.0 months; P…

medicine.medical_specialtyMultivariate analysisCarcinoma HepatocellularIndependent predictorGastroenterologyResection03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalHepatectomyHumansStaging systemNeoplasm StagingRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologytreatmentbusiness.industrySettore MED/09 - MEDICINA INTERNALiver Neoplasmsbclc staging systemmonofocal hepatocellular carcinomamedicine.diseasedigestive system diseasesSurvival benefitItaly030220 oncology & carcinogenesisHepatocellular carcinomabclc staging system; liver resection; monofocal hepatocellular carcinoma; prognosis; treatmentliver resection030211 gastroenterology & hepatologyprognosisbusinessLiver cancerprognosi
researchProduct